{"disease":{"id":"tnbc-triple-negative-breast-cancer","name":"tnbc triple negative breast cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05862064","title":"A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":606,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT05867251","title":"Study of AVZO-021 in Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":430,"lead_sponsor_name":"Avenzo Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05999149","title":"A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":424,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06230185","title":"CtDNA Based MRD Testing for NAC Monitoring in TNBC","phase":"","overall_status":"RECRUITING","enrollment_count":422,"lead_sponsor_name":"Personalis Inc.","has_results":false},{"nct_id":"NCT06627712","title":"SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":318,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT03207867","title":"A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":315,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05396612","title":"Role of the Immune Environment in Response to Therapy in Breast Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Abramson Cancer Center at Penn Medicine","has_results":false},{"nct_id":"NCT06798506","title":"Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Triple-negative Breast Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT03219268","title":"A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":277,"lead_sponsor_name":"MacroGenics","has_results":false},{"nct_id":"NCT05768932","title":"BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"SillaJen, Inc.","has_results":false},{"nct_id":"NCT06534762","title":"Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"Zhejiang Provincial People's Hospital","has_results":false},{"nct_id":"NCT07256964","title":"Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":216,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT07523789","title":"Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":201,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT04799249","title":"Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":194,"lead_sponsor_name":"G1 Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05933265","title":"Study of LP-184 in Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":175,"lead_sponsor_name":"Lantern Pharma Inc.","has_results":false},{"nct_id":"NCT04395989","title":"An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":139,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT05928780","title":"An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":125,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT07101614","title":"A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC).","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":125,"lead_sponsor_name":"Shengjing Hospital","has_results":false},{"nct_id":"NCT07080619","title":"SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Tianjin ConjuStar Biologics Co., Ltd.","has_results":false},{"nct_id":"NCT05541367","title":"Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT06125080","title":"The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":78,"lead_sponsor_name":"Huihua Xiong","has_results":false},{"nct_id":"NCT06387628","title":"LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":74,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06404736","title":"QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":73,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT07321015","title":"A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":72,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT05834582","title":"Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT05585034","title":"Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT06786026","title":"QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT05274451","title":"A Study to Investigate LYL797 in Adults With Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":57,"lead_sponsor_name":"Lyell Immunopharma, Inc.","has_results":false},{"nct_id":"NCT07327021","title":"MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Tel-Aviv Sourasky Medical Center","has_results":false},{"nct_id":"NCT03057600","title":"Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Calithera Biosciences, Inc","has_results":true},{"nct_id":"NCT06819319","title":"SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":52,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT07244874","title":"Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":41,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT07351487","title":"Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":37,"lead_sponsor_name":"First Affiliated Hospital of Zhejiang University","has_results":false},{"nct_id":"NCT05660083","title":"Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"The Methodist Hospital Research Institute","has_results":false},{"nct_id":"NCT05491226","title":"Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":35,"lead_sponsor_name":"Stephen Shiao","has_results":false},{"nct_id":"NCT06682195","title":"Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"First Affiliated Hospital of Zhejiang University","has_results":false},{"nct_id":"NCT03719326","title":"A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Arcus Biosciences, Inc.","has_results":false},{"nct_id":"NCT03875313","title":"Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":33,"lead_sponsor_name":"Calithera Biosciences, Inc","has_results":true},{"nct_id":"NCT07271992","title":"TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"First Hospital of China Medical University","has_results":false},{"nct_id":"NCT06220214","title":"Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Alison Stopeck","has_results":false},{"nct_id":"NCT07178171","title":"A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Xijing Hospital","has_results":false},{"nct_id":"NCT05402722","title":"Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Beijing 302 Hospital","has_results":false},{"nct_id":"NCT07441512","title":"A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":26,"lead_sponsor_name":"Hu Hai","has_results":false},{"nct_id":"NCT05390710","title":"PhI to Solid Tumors and PhII to Locally Advanced or mTNBC","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Laekna Limited","has_results":false},{"nct_id":"NCT05491694","title":"To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT07046455","title":"Trop-2 Targeted PET Probes in Advanced TNBC","phase":"NA","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT03199040","title":"Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":18,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT07457359","title":"Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT06637306","title":"Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"Rima Patel","has_results":false},{"nct_id":"NCT05219578","title":"RTX-224 Monotherapy in Patients With Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":7,"lead_sponsor_name":"Rubius Therapeutics","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}